Technology | March 28, 2011

FDA Approves Two Cardiac Resynchronization Therapy-Pacemaker Systems

March 28, 2011 – The U.S. Food and Drug Administration (FDA) has approved two new cardiac resynchronization therapy-pacemaker (CRT-P) systems. The Consulta and Syncra CRT-P systems, from Medtronic, are the first to include OptiVol Fluid Status Monitoring.

The feature identifies patients at risk for worsening heart failure before symptoms develop.

Additionally, both Consulta and Syncra are the first CRT?Ps that include Leadless ECG Waveform. Together with the Medtronic CareLink Network device data monitoring system, the systems offer the possibility of remote follow?up in heart failure patients implanted with these devices. Shipments will begin immediately.

“Atrial arrhythmias are the number one cause of reduced cardiac resynchronization therapy; therefore, there is a real need for next?generation devices that can deliver lifesaving CRT in this patient population,” said Robert Canby, M.D., Texas Cardiac Arrhythmia and Seton Medical Center, Austin, Texas. “These new innovative technologies allow physicians to proactively manage their heart failure patients, and offer cutting?edge features that contribute to patient safety and physician ease?of?use.”

Both next?generation systems provide fully automatic capabilities and adaptive therapies that help to ensure CRT, even during atrial fibrillation, and enable physicians to monitor their heart failure patients in the office or remotely. Additionally, both systems include unique programming flexibility to avoid phrenic nerve stimulation, which helps prevent the need for more invasive surgical approaches.

While both systems include the same technology, they have differentiating features. Consulta includes the company’s OptiVol Fluid Status Monitoring, as well as Complete Capture Management, which monitors and adjusts to patient needs automatically and can positively impact device longevity and reduce in?office testing.

Cardiac resynchronization therapy (CRT), also known as bi?ventricular pacing, is a treatment for heart failure that uses an implantable device to improve the pumping efficiency of the heart. A cardiac resynchronization therapy?pacemaker is a stopwatch?sized device implanted in the upper chest to resynchronize the contractions of the ventricles. It sends tiny electrical pacing impulses to the heart muscle via leads (thin wires) to help the heart pump blood throughout the body more efficiently, reduce symptoms and help decrease mortality. CRT is intended to complement standard drug treatment, and dietary and lifestyle modifications.

For more information: www.medtronic.com

Related Content

News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
CMS, additional participants, Bundled Payments for Care Improvement initiative, Medicare, eipsodes of care
News | Business| August 17, 2015
The Centers for Medicare & Medicaid Service (CMS) announced that over 2,100 healthcare facilities have agreed to...
Biotronik, BIOGUARD-MI Study, BioMonitor, cardiac arrhythmias, early detection, remote monitoring
News | Implantable Cardiac Monitor (ICM)| August 11, 2015
Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early...
Boston Scientific, Preventice Solutions, equity investment, sales cooperation agreement, cardiac monitoring

BodyGuardian product family. Image courtesy of Preventice Solutions.

News | Remote Monitoring| August 11, 2015
Boston Scientific has become a significant shareholder and will become the exclusive worldwide sales and marketing...
Passive Elastography, TTP, U.K., ablation, atrial fibrillation
News | Cardiovascular Ultrasound| August 10, 2015
The Technology Partnership (TTP), a U.K.-based research and product development company, has made major advances in the...
Biotronik, CE approval, 3T MRI scanning, pacemakers, ICDs
News | Implantable Cardioverter Defibrillators (ICD)| August 03, 2015
Biotronik announced CE approval of 3 Tesla (T) magnetic resonance imaging (MRI) scanning with exclusion zone for its...
Overlay Init